Managing Non-acute Subdural Hematoma Using Liquid Materials:a Chinese Randomized Trial of MMA Treatment (MAGIC-MT)
Primary Purpose
Subdural Hematoma, Non-acute
Status
Active
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Onyx
Burr-hole
Medical Management
Sponsored by
About this trial
This is an interventional treatment trial for Subdural Hematoma, Non-acute
Eligibility Criteria
Inclusion Criteria:
Symptomatic non-acute SDH with mass effect (i.e. chronic or subacute SDH, fulfilling one or more of the following criteria)
- <30% hyperdense components
- septations that are indicative of a chronic SDH
- known from previous (>2 weeks old) brain imaging Mass effect is defined as midline shift or deformation of the normal contour of the brain (i.e. flattening) due to the SDH.
Symptomatic SDH is defined as an SDH that fulfills one or more of the following criteria AND shows neurological symptoms (headache, short-term cognitive decline, speech difficulty or aphasia, gait impairment, focal weakness, sensory deficits, seizures) that are attributable to the hematoma
- Age 18 or higher
- Independent functional status in activities of daily living with mRS score ≤ 2 prior to the symptom.
- Signed informed consent or appropriate signed deferral of consent where approved.
Exclusion Criteria:
- Qualifying imaging reveals clear hypodense demarcation of the majority of the territory of symptomatic intracranial occlusion.
- Subject requires (in the opinion of the treating surgeon) a full or mini craniotomy.
- Subject with urgent or emergent subdural hematoma evacuation needed.
- Bilateral SDH with unknown origin of symptoms.
- Any evidence of anatomical variants that might render safe MMA embolization impossible (e.g. prominent MMA-ophtalmic artery anastomoses)
- Coagulation and platelet disorders, or antiplatelet medication that is not easily correctable with INR >1.5 and/or platelet count < 80.000.
- Contraindications for neurangiography, e.g. iodinated contrast allergy, renal insufficiency with GFR < 30 ml/min.
- CT or MRI evidence of intra-cranial tumor or mass lesion.
- Pregnancy; if a woman is of child-bearing potential a urine or serum beta HCG test is positive.
- Patient has a severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient.
- Life expectancy <1 year.
- High risk of removal from antiplatelet and/or anticoagulant medical therapy for recent procedure or other reasons.
- Patient cannot complete follow-up for any reason. (eg. visiting from another city, illness, incarceration in prison etc.)
- Participation in another clinical trial investigating a drug, medical device, or a medical procedure that might confound treatment and outcomes related to the current trial.
- Previous surgery or endovascular treatment for the SDH under investigation
- Unable to undergo MMA embolization prior to surgical treatment.
Sites / Locations
- Huashan Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Embolization
No embolization
Arm Description
Middle meningeal artery(MMA) embolization
Traditional treatment group
Outcomes
Primary Outcome Measures
Incidence of symptomatic SDH recurrence/ progression within 90 days post-procedure
SDH recurrence (>10 mm max. thickness) or receiving re-operation in patients who underwent surgery/ symptomatic SDH progression (>3 mm increase in max thickness or receiving surgical rescue in patients who did not undergo sugery) at 90 days
"Symptomatic" is hereby defined as one or more of the following features which are attributed to the progression/recurrence: headache, short-term cognitive decline, speech difficulty or aphasia, gait impairment, focal weakness, sensory deficits, seizures
Secondary Outcome Measures
Effectiveness
Incidence of SDH recurrence/ progression at 1 year post-procedure
Effectiveness
Rate of successful embolization of the target vessels (MMA trunk and branches) with ONYX base on DSA imaging
Effectiveness
Change in hematoma thickness based on CT/MRI imaging at 90 days post-procedure
Effectiveness
Changes in hematoma volume at 90 days post-procedure
Effectiveness
Change in Midline shift based on CT/MRI imaging at 90 days post-procedure
Effectiveness
Change in the Modified Rankin Scale score (mRS) Grade 0 (no symptoms) to 6 (death) at 90 days and 1 year post-procedure
Effectiveness
Percentage of patients with favorable functional outcome defined as Modified Rankin Scale of 0 to 3 at 90 days and 1year post-procedure
Effectiveness
Percentage of patients with good functional outcome defined as Modified Rankin Scale of 0 to 2 at 90 days and 1 year post-procedure
Effectiveness
Quality of life assessed by (EuroQol) EQ-5D scale Grade 0 (worst health) to 100 (best health) at 90 days and 1 year post-procedure
Safety endpoint
Total patients with SAEs within 90 days post-procedure
Safety endpoint
Incidence of neurological death within 90 days post-procedure
Safety endpoint
Incidence of procedural serious complications within 30 days post-procedure:
symptomatic procedure-related intracranial hemorrhage
any procedure-related intracranial hemorrhage
any procedure-related neurological deficit
CNS infection caused by procedure
procedure-related artery dissection, vessel wall damage and vessel perforation
procedure-related ischemic event
retroperitoneal hematoma (femoral access)/wrist hematoma (radial access)
neuropathy at the puncture site
contrast agent allergy or encephalopathy
Full Information
NCT ID
NCT04700345
First Posted
January 4, 2021
Last Updated
August 20, 2023
Sponsor
Huashan Hospital
Collaborators
Changhai Hospital, Shanghai Shen Kang Hospital Development Center
1. Study Identification
Unique Protocol Identification Number
NCT04700345
Brief Title
Managing Non-acute Subdural Hematoma Using Liquid Materials:a Chinese Randomized Trial of MMA Treatment
Acronym
MAGIC-MT
Official Title
Managing Non-acute Subdural Hematoma Using Liquid Materials:a Chinese Randomized Trial of MMA Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 21, 2021 (Actual)
Primary Completion Date
August 16, 2023 (Anticipated)
Study Completion Date
May 16, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Huashan Hospital
Collaborators
Changhai Hospital, Shanghai Shen Kang Hospital Development Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
MAGIC-MT study is multi-center, prospective, randomized (1:1) controlled trial designed to show that additional MMA embolization with Onyx in patients with non-acute symptomatic subdural hematoma(SDH) results in reduced hematoma recurrence in surgically treated patients/ reduced hematoma progression in conservatively managed patients.
Detailed Description
The objective of this study is to show that additional MMA embolization with Onyx in patients with non-acute symptomatic subdural hematoma(SDH) results in reduced hematoma recurrence in surgically treated patients/ reduced hematoma progression in conservatively managed patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Subdural Hematoma, Non-acute
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
722 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Embolization
Arm Type
Experimental
Arm Description
Middle meningeal artery(MMA) embolization
Arm Title
No embolization
Arm Type
Active Comparator
Arm Description
Traditional treatment group
Intervention Type
Device
Intervention Name(s)
Onyx
Intervention Description
Embolization of the Middle Meningeal Artery using the liquid embolic material
Intervention Type
Procedure
Intervention Name(s)
Burr-hole
Intervention Description
Burr-hole drainage of subdural hematoma
Intervention Type
Other
Intervention Name(s)
Medical Management
Intervention Description
best medical management
Primary Outcome Measure Information:
Title
Incidence of symptomatic SDH recurrence/ progression within 90 days post-procedure
Description
SDH recurrence (>10 mm max. thickness) or receiving re-operation in patients who underwent surgery/ symptomatic SDH progression (>3 mm increase in max thickness or receiving surgical rescue in patients who did not undergo sugery) at 90 days
"Symptomatic" is hereby defined as one or more of the following features which are attributed to the progression/recurrence: headache, short-term cognitive decline, speech difficulty or aphasia, gait impairment, focal weakness, sensory deficits, seizures
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Effectiveness
Description
Incidence of SDH recurrence/ progression at 1 year post-procedure
Time Frame
1 year post-procedure
Title
Effectiveness
Description
Rate of successful embolization of the target vessels (MMA trunk and branches) with ONYX base on DSA imaging
Time Frame
day 0
Title
Effectiveness
Description
Change in hematoma thickness based on CT/MRI imaging at 90 days post-procedure
Time Frame
90 days post-procedure
Title
Effectiveness
Description
Changes in hematoma volume at 90 days post-procedure
Time Frame
90 days post-procedure
Title
Effectiveness
Description
Change in Midline shift based on CT/MRI imaging at 90 days post-procedure
Time Frame
90 days post-procedure
Title
Effectiveness
Description
Change in the Modified Rankin Scale score (mRS) Grade 0 (no symptoms) to 6 (death) at 90 days and 1 year post-procedure
Time Frame
90 days and 1 year post-procedure
Title
Effectiveness
Description
Percentage of patients with favorable functional outcome defined as Modified Rankin Scale of 0 to 3 at 90 days and 1year post-procedure
Time Frame
90 days and 1 year post-procedure
Title
Effectiveness
Description
Percentage of patients with good functional outcome defined as Modified Rankin Scale of 0 to 2 at 90 days and 1 year post-procedure
Time Frame
90 days and 1 year post-procedure
Title
Effectiveness
Description
Quality of life assessed by (EuroQol) EQ-5D scale Grade 0 (worst health) to 100 (best health) at 90 days and 1 year post-procedure
Time Frame
90 days and 1 year post-procedure
Title
Safety endpoint
Description
Total patients with SAEs within 90 days post-procedure
Time Frame
90 days
Title
Safety endpoint
Description
Incidence of neurological death within 90 days post-procedure
Time Frame
90 days
Title
Safety endpoint
Description
Incidence of procedural serious complications within 30 days post-procedure:
symptomatic procedure-related intracranial hemorrhage
any procedure-related intracranial hemorrhage
any procedure-related neurological deficit
CNS infection caused by procedure
procedure-related artery dissection, vessel wall damage and vessel perforation
procedure-related ischemic event
retroperitoneal hematoma (femoral access)/wrist hematoma (radial access)
neuropathy at the puncture site
contrast agent allergy or encephalopathy
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Symptomatic non-acute SDH with mass effect (i.e. chronic or subacute SDH, fulfilling one or more of the following criteria)
<30% hyperdense components
septations that are indicative of a chronic SDH
known from previous (>2 weeks old) brain imaging Mass effect is defined as midline shift or deformation of the normal contour of the brain (i.e. flattening) due to the SDH.
Symptomatic SDH is defined as an SDH that fulfills one or more of the following criteria AND shows neurological symptoms (headache, short-term cognitive decline, speech difficulty or aphasia, gait impairment, focal weakness, sensory deficits, seizures) that are attributable to the hematoma
Age 18 or higher
Independent functional status in activities of daily living with mRS score ≤ 2 prior to the symptom.
Signed informed consent or appropriate signed deferral of consent where approved.
Exclusion Criteria:
Qualifying imaging reveals clear hypodense demarcation of the majority of the territory of symptomatic intracranial occlusion.
Subject requires (in the opinion of the treating surgeon) a full or mini craniotomy.
Subject with urgent or emergent subdural hematoma evacuation needed.
Bilateral SDH with unknown origin of symptoms.
Any evidence of anatomical variants that might render safe MMA embolization impossible (e.g. prominent MMA-ophtalmic artery anastomoses)
Coagulation and platelet disorders, or antiplatelet medication that is not easily correctable with INR >1.5 and/or platelet count < 80.000.
Contraindications for neurangiography, e.g. iodinated contrast allergy, renal insufficiency with GFR < 30 ml/min.
CT or MRI evidence of intra-cranial tumor or mass lesion.
Pregnancy; if a woman is of child-bearing potential a urine or serum beta HCG test is positive.
Patient has a severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient.
Life expectancy <1 year.
High risk of removal from antiplatelet and/or anticoagulant medical therapy for recent procedure or other reasons.
Patient cannot complete follow-up for any reason. (eg. visiting from another city, illness, incarceration in prison etc.)
Participation in another clinical trial investigating a drug, medical device, or a medical procedure that might confound treatment and outcomes related to the current trial.
Previous surgery or endovascular treatment for the SDH under investigation
Unable to undergo MMA embolization prior to surgical treatment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ying Mao, PhD
Organizational Affiliation
department of Neurosurgery, Huashan Hospital,Fudan University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jian Min Liu, MD
Organizational Affiliation
department of Neurosurgery, Changhai Hospital of the Second Military Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Huashan Hospital
City
Shanghai
State/Province
Shanghai
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Managing Non-acute Subdural Hematoma Using Liquid Materials:a Chinese Randomized Trial of MMA Treatment
We'll reach out to this number within 24 hrs